Does the media refer more to LNTH or TRVI?

In the previous week, Lantheus had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Lantheus' score of 0.79 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TRVI or AMRX?

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Amneal Pharmaceuticals' score of 0.54 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, BLTE or TRVI?

Belite Bio is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is BLTE or TRVI more profitable?

Belite Bio's return on equity of -11.84% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Trevi Therapeutics N/A -23.59% -22.64%

Does the media favor BLTE or TRVI?

In the previous week, Belite Bio had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Belite Bio's score of 0.68 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, DFTX or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is DFTX or TRVI more profitable?

Trevi Therapeutics' return on equity of -23.59% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Trevi Therapeutics N/A -23.59% -22.64%

Does the media refer more to DFTX or TRVI?

In the previous week, Definium Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for Definium Therapeutics and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Definium Therapeutics' score of 0.83 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TRVI or MANE?

Veradermics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A Veradermics N/A N/A -$70M -$1.90 N/A

Is TRVI or MANE more profitable?

Veradermics' return on equity of 0.00% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Veradermics N/A N/A N/A

Does the media prefer TRVI or MANE?

In the previous week, Veradermics had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Veradermics and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Veradermics' score of 0.38 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Trevi Therapeutics (TRVI) Competitors

$13.19 +0.37 (+2.89%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$13.20 +0.01 (+0.04%)

As of 10/9/2026 07:30 PM Eastern

Compare

TRVI vs. LNTH, AMRX, BLTE, DFTX, and MANE

Should you buy Trevi Therapeutics stock or one of its competitors? Trevi Therapeutics's main competitors and comparable companies include Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Belite Bio (BLTE), Definium Therapeutics (DFTX), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trevi Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Lantheus presently has a consensus target price of $108.11, suggesting a potential upside of 7.95%. Trevi Therapeutics has a consensus target price of $27.08, suggesting a potential upside of 105.33%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Lantheus had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Lantheus' score of 0.79 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

Lantheus has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.19
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Lantheus has a net margin of 17.69% compared to Trevi Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Summary

Lantheus beats Trevi Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Amneal Pharmaceuticals?

Trevi Therapeutics (NASDAQ:TRVI) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Trevi Therapeutics presently has a consensus price target of $27.08, indicating a potential upside of 105.33%. Amneal Pharmaceuticals has a consensus price target of $21.00, indicating a potential upside of 5.47%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Trevi Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Trevi Therapeutics' net margin of 0.00%. Trevi Therapeutics' return on equity of -23.59% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Trevi Therapeutics. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Amneal Pharmaceuticals' score of 0.54 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Amneal Pharmaceuticals	$3.02B	2.11	$72.06M	$0.49	40.63

Summary

Amneal Pharmaceuticals beats Trevi Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Belite Bio's return on equity of -11.84% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Belite Bio is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Belite Bio currently has a consensus target price of $218.73, suggesting a potential upside of 41.58%. Trevi Therapeutics has a consensus target price of $27.08, suggesting a potential upside of 105.33%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Belite Bio had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Belite Bio's score of 0.68 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Trevi Therapeutics beats Belite Bio on 11 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Definium Therapeutics has a beta of 2.19, suggesting that its stock price is 119% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Trevi Therapeutics' return on equity of -23.59% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Definium Therapeutics presently has a consensus target price of $66.00, suggesting a potential upside of 78.86%. Trevi Therapeutics has a consensus target price of $27.08, suggesting a potential upside of 105.33%. Given Trevi Therapeutics' higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.00
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Definium Therapeutics had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 4 mentions for Definium Therapeutics and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Definium Therapeutics' score of 0.83 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Trevi Therapeutics beats Definium Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to Veradermics?

Trevi Therapeutics (NASDAQ:TRVI) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

95.8% of Trevi Therapeutics shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Trevi Therapeutics currently has a consensus price target of $27.08, indicating a potential upside of 105.33%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 17.00%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Trevi Therapeutics is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Veradermics' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Veradermics	N/A	N/A	N/A

In the previous week, Veradermics had 2 more articles in the media than Trevi Therapeutics. MarketBeat recorded 5 mentions for Veradermics and 3 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.26 beat Veradermics' score of 0.38 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Trevi Therapeutics beats Veradermics on 10 of the 13 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.88B	$12.40B	$7.25B	$13.30B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	-38.79	797.58	275.01	26.14
Price / Sales	N/A	751.21	582.85	87.88
Price / Cash	N/A	86.66	76.96	53.71
Price / Book	9.22	10.71	11.22	6.33
Net Income	-$42.76M	$2.84B	$3.50B	$382.15M
7 Day Performance	-5.18%	-0.94%	-0.89%	-1.40%
1 Month Performance	-17.04%	-3.67%	-4.02%	-3.35%
1 Year Performance	32.03%	-3.97%	7.13%	1.49%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	2.9748 of 5 stars	$13.19 +2.9%	$27.08 +105.3%	+32.0%	$1.88B	N/A	N/A	34	Positive News Analyst Forecast Options Volume Gap Up High Trading Volume
LNTH Lantheus	3.7645 of 5 stars	$100.15 +0.2%	$108.11 +8.0%	+87.1%	$6.54B	$1.54B	24.19	1,193
AMRX Amneal Pharmaceuticals	3.8559 of 5 stars	$19.97 -1.6%	$21.00 +5.2%	+99.7%	$6.38B	$3.02B	40.75	8,500	Analyst Downgrade
BLTE Belite Bio	2.9936 of 5 stars	$155.75 +0.1%	$218.73 +40.4%	+94.9%	$6.27B	N/A	N/A	41
DFTX Definium Therapeutics	3.5393 of 5 stars	$35.84 +0.6%	$64.88 +81.0%	+212.4%	$4.82B	N/A	N/A	40	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. LNTH, AMRX, BLTE, DFTX, and MANE

How does Trevi Therapeutics compare to Lantheus?

Summary

How does Trevi Therapeutics compare to Amneal Pharmaceuticals?

Summary

How does Trevi Therapeutics compare to Belite Bio?

Summary

How does Trevi Therapeutics compare to Definium Therapeutics?

Summary

How does Trevi Therapeutics compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. LNTH, AMRX, BLTE, DFTX, and MANE

How does Trevi Therapeutics compare to Lantheus?

Do analysts prefer LNTH or TRVI?

Does the media refer more to LNTH or TRVI?

Do institutionals and insiders believe in LNTH or TRVI?

Which has more volatility & risk, LNTH or TRVI?

Which has higher valuation and earnings, LNTH or TRVI?

Is LNTH or TRVI more profitable?

Summary

How does Trevi Therapeutics compare to Amneal Pharmaceuticals?

Do analysts recommend TRVI or AMRX?

Which has more risk and volatility, TRVI or AMRX?

Is TRVI or AMRX more profitable?

Do institutionals and insiders have more ownership in TRVI or AMRX?

Does the media favor TRVI or AMRX?

Which has stronger valuation and earnings, TRVI or AMRX?

Summary

How does Trevi Therapeutics compare to Belite Bio?

Which has more volatility and risk, BLTE or TRVI?

Do institutionals & insiders hold more shares of BLTE or TRVI?

Is BLTE or TRVI more profitable?

Which has higher earnings & valuation, BLTE or TRVI?

Do analysts prefer BLTE or TRVI?

Does the media favor BLTE or TRVI?

Summary

How does Trevi Therapeutics compare to Definium Therapeutics?

Which has better earnings & valuation, DFTX or TRVI?

Which has more risk & volatility, DFTX or TRVI?

Is DFTX or TRVI more profitable?

Do analysts recommend DFTX or TRVI?

Does the media refer more to DFTX or TRVI?

Do insiders and institutionals hold more shares of DFTX or TRVI?

Summary

How does Trevi Therapeutics compare to Veradermics?

Do insiders & institutionals have more ownership in TRVI or MANE?

Do analysts rate TRVI or MANE?

Which has stronger earnings and valuation, TRVI or MANE?

Is TRVI or MANE more profitable?

Does the media prefer TRVI or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools